In the context of osteosarcoma, abnormal activation of NF-κB contributes to the development of a pro-tumorigenic TME that encourages tumor growth, metastasis, and resistance to conventional therapies such as chemotherapy and radiotherapy. Here, NFKB1 is linked to osteosarcoma.